Vera Therapeutics (VERA) Total Non-Current Liabilities (2020 - 2026)

Vera Therapeutics has reported Total Non-Current Liabilities for 7 years, with the latest figure at $120.2 million in Q1 2026.

• For the quarter ending Q1 2026, Total Non-Current Liabilities changed N/A year-over-year to $120.2 million; the trailing twelve-month figure through Mar 2026 stood at $120.2 million (changed N/A YoY), and the FY2025 full-year result was $128.3 million, up 63.38% from the prior year.
• Total Non-Current Liabilities for Q1 2026 stood at $120.2 million, down from $128.3 million in the prior quarter.
• The five-year high for Total Non-Current Liabilities was $128.3 million in Q4 2025, with the low at $25.4 million in Q3 2022.
• Historically, Total Non-Current Liabilities has averaged $64.9 million across 5 years, with a median of $59.9 million in 2023.
• Annual changes were most pronounced in 2022 — Total Non-Current Liabilities jumped 565.32% — and 2024, when it gained 6.73%.
• Vera Therapeutics' Total Non-Current Liabilities stood at $54.2 million in 2022, then soared by 35.64% to $73.6 million in 2023, then increased by 6.73% to $78.5 million in 2024, then jumped by 63.38% to $128.3 million in 2025, then slipped by 6.33% to $120.2 million in 2026.
• The last three Total Non-Current Liabilities figures came in at $120.2 million (Q1 2026), $128.3 million (Q4 2025), and $78.5 million (Q4 2024), per Business Quant data.